Get to know our clinical trials

Extension study for participants with advanced tumors in trials of pembrolizumab

THE PURPOSE OF THIS STUDY IS TO CONTINUE TO COLLECT LONG-TERM INFORMATION ABOUT THE SAFETY OF PEMBROLIZUMAB OR PEMBROLIZUMAB-BASED COMBINATIONS THAT YOU RECEIVED OR ARE RECEIVING AS PART OF THE PROTOCOL IN WHICH YOU ARE CURRENTLY PARTICIPATING, IN ORDER TO SEE HOW THE DRUGS WORK AND HOW YOUR BODY REACTS TO THEM OVER THE LONG TERM.

Diseases
Inmunoterapia, vacunas contra el cáncer
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • EXTENSION STUDY FOR PARTICIPANTS WITH ADVANCED TUMORS IN PEMBROLIZUMAB TRIALS. IMMUNOTHERAPY
  • Code EudraCT: 2017-004417-42
  • Protocol number: MK-3475-587
  • Promoter: Merck Sharp & Dohme, S.A.
  • Molecule/Drug: PEMBROLIZUMAB

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.